RxDoctor Payments Data

Michael Kaplan, MD

Otolaryngology · Houston, TXNPI 1750443289

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $181,213 of the $201,980 with a category attached, or 89.7%. Stryker accounts for 91.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $102,670 and has fallen 86.9% since, to $13,460 in 2025. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$201,980in general payments, 2019–2025

Across 374 payments — averaging $540.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$185K
  • Neurent Medical Limited$12K
  • Intersect ENT, Inc.$2K
  • Medtronic$569
  • GSK$394
  • Optinose US, Inc.$315
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$181,21390%
  • Travel & lodging$5,1983%
  • Food & beverage$15,5708%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$201,980 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas

Medicare billing

Part B allowed, 2024
$3,855,875
Medicare patients
263
Services billed
5,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate15$9,630
Ipratropium Bromide94$2,331
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen249$1,001
Amoxicillin243$647
Prednisone186$342
Methylprednisolone52$325
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav42$291
Ciprofloxacin Hcl25$282
Doxycycline Hyclate30$251
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim46$208
Pantoprazole Sodium12$142
Lorazepam106$126
Levofloxacin22$125
Mupirocin13$95
Promethazine Hcl51$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$315$9,63015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 otolaryngology providers in Texas.

Other otolaryngology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →